ICLR — ICON plc

Is ICLR overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Diagnostics & Research

Strong Oversold As of October 3, 2026

ICON plc (ICLR) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Diagnostics & Research) last closed at $162.05. The rating moved from Overbought to Strong Oversold on October 1, 2026.

See all oversold Healthcare stocks →

AI analysis

ICON plc (ICLR) sits well-positioned as a leading CRO benefiting from multi-year outsourcing trends and steady late-stage biotech demand. Near-term sentiment is subdued given market risk-off and delayed healthcare/device IPOs, which can slow new study starts, but ongoing large, late-stage programs and a solid backlog provide revenue visibility and margin upside as operations scale. Key risks include funding pullbacks from sponsors, competitive pricing pressure, and operational/clinical delays tied to geopolitical and supply-chain disruptions. The balance of steady cash generation, investments in digital capabilities, and exposure to late-stage biologics underpins a constructive medium-term outlook with episodic volatility possible.

Key factors

  • Leading global CRO with diversified service set across phases I–IV and strong client portfolio including big pharma and specialty biotech
  • Structural secular trend of increased outsourcing of clinical development supports multi-year revenue visibility and backlog
  • Late-stage biologics and specialty biotech momentum should sustain demand for late-stage and commercialization services
  • Historically solid margin profile with operating leverage potential as larger programs and tech-enabled offerings scale
  • Relatively strong balance sheet and cash generation that supports investment in digital/analytics capabilities and opportunistic M&A
  • Market caution and episodic trial delays create near-term volatility but do not structurally impair contracted revenues for ongoing large programs

Risks

  • Macro risk-off that delays biotech/device IPOs and early-stage funding, reducing near-term new study starts and sponsor budgets
  • Policy and payer pressures (e.g., Medicare drug-price negotiation) that could alter sponsor R&D prioritization and pricing power
  • Intense competition from other large CROs and niche providers which could pressure pricing and win rates
  • Operational execution risk on large programs, integration risk from acquisitions, and potential project cost overruns
  • Geopolitical disruptions and supply-chain issues that can delay patient enrollment and site activation
  • Foreign-exchange exposure and reimbursement/clinical-regulatory changes across jurisdictions
  • Client concentration risk where slowdown at a few large sponsors could materially affect short-term revenue

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for ICLR — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.